Cargando…
Health Canada’s use of expedited review pathways and therapeutic innovation, 1995–2016: cross-sectional analysis
OBJECTIVES: This study examines the use of expedited approval pathways by Health Canada over the period 1995 to 2016 inclusive and the relationship between the use of these pathways and the therapeutic gain offered by new products. DESIGN: Cross-sectional study. DATA SOURCES: Therapeutic Products Di...
Autor principal: | Lexchin, Joel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119438/ https://www.ncbi.nlm.nih.gov/pubmed/30166310 http://dx.doi.org/10.1136/bmjopen-2018-023605 |
Ejemplares similares
-
Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study
por: Lexchin, Joel
Publicado: (2023) -
National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022) -
Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
por: Lexchin, Joel
Publicado: (2014) -
A cross-sectional analysis of the relationship between diabetes and health access barriers in an urban First Nations population in Canada
por: Beckett, Michael, et al.
Publicado: (2018) -
How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2016)